Barclays sets a USD 24.00 target for Kura Oncology stock

Published on 10/24/2026 at 19:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Kura revenue reached USD 20.87 million in the second quarter versus USD 20.16 million expected. Kura Oncology stock costs EUR 8.50 on October 24, 2026 at 1:04 p.m. CEST.

Barclays target and quarterly figures

Barclays set a USD 24.00 target for Kura Oncology stock on October 14, 2026.
Second-quarter 2026 revenue reached USD 20.87 million against USD 20.16 million expected.
Kura Oncology stock costs EUR 8.50 at Lang & Schwarz on October 24, 2026 at 1:04 p.m. CEST.
Kura Oncology is scheduled to report earnings on November 3, 2026.

KURA, US50127T1097, Illustration mit AI erstellt.

Kura Oncology (ISIN US50127T1097) drew a fresh analyst target after Barclays set a USD 24.00 price target on October 14, 2026, according to MarketBeat. Against the Nasdaq price of USD 9.61 on October 23, 2026, that target stood 149.74 percent higher. Kura Oncology was trading at EUR 8.50 at Lang & Schwarz on October 24, 2026 at 1:04 p.m. CEST.

Revenue beats quarterly expectations

Kura reported USD 20.87 million in revenue for the second quarter of 2026, compared with USD 20.16 million expected. The company also posted a diluted loss of USD 0.77 per share, versus a consensus loss of USD 0.88 per share, according to MarketBeat. The revenue comparison represents a USD 0.71 million beat, while the per-share loss was USD 0.11 narrower than expected.

Stock sits inside its yearly range

On the Nasdaq, Kura last traded at USD 9.61 on October 23, 2026, with a market capitalization of USD 854.9 million and volume of 1,564,976 shares. The 52-week range ran from USD 7.36 to USD 13.90, placing the stock 30.57 percent above its low and 30.86 percent below its high.

Losses shape the valuation picture

Kura's price-to-earnings ratio was negative 2.85 on October 23, 2026, reflecting the company's loss-making profile. Its next earnings date is November 3, 2026, as listed by Stock Analysis.

What the target says about valuation

Barclays' USD 24.00 target is materially above the latest Nasdaq price, while the second-quarter revenue beat provides a concrete operating reference. The contrast is important because Kura's commercial progress is being measured alongside continuing losses and a negative price-to-earnings ratio.

Price and next reporting date

Kura Oncology was trading at EUR 8.50 at Lang & Schwarz on October 24, 2026 at 1:04 p.m. CEST. On the Nasdaq, the stock closed at USD 9.61 on October 23, 2026.

The further course of trading is shown by the continuously updated real-time quote of Kura Oncology stock.